×

Niklas Carlén Appointed Interim CEO of Stille AB

Torbjörn Sköld will begin his tenure as new Stille’s new CEO on March 20th, 2023, where he will replace Hanna Ernestam Wilkman who has been the company’s CEO since April 1st, 2019. Stille’s board of directors have decided to appoint Niklas Carlén as Interim CEO up until Torbjörn will commence his employment. Niklas has been…

Torbjörn Sköld will begin his tenure as new Stille’s new CEO on March 20th, 2023, where he will replace Hanna Ernestam Wilkman who has been the company’s CEO since April 1st, 2019. Stille’s board of directors have decided to appoint Niklas Carlén as Interim CEO up until Torbjörn will commence his employment. Niklas has been the company’s CFO since June 2020.

Torshälla, January 25th, 2023.

This information is such information that Stille AB is obliged to disclose according to the EU’s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on January 25th, 2023, kl. 15.50 (CET).

Attachments

Press Release - Niklas Carlén Appointed Interim CEO

For more information, please contact:

Lars Kvarnhem
Chairman of the Board

+46 (0)70 512 00 21 | lars.kvarnhem@priego.se

Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.


Subscribe to our news!

Enter your details and get the latest news straight to your inbox